


24/15

Colin ✓ 20/2 file

Did Charles factor his
cost into the downside
case against recombinant?



Charles Lister
14/02/2001 13:10

Sent by: Charles Lister/HSD2

To: Alex Berland/HSD2/DOH/GB@GRO-C
Mike McGovern/HSD2/DOH/GB@GRO-C
Keith Paley/FPA-FAS/DOH/GB@GRO-C
Jill Taylor/HSD7/DOH/GB@GRO-C
Margaret Ghilaimi/HSD7/DOH/GB@GRO-C

cc:

Subject: RECOMBINANT CLOTTING FACTORS: IMPACT ON BPL

GRO-C

15/2

You might like to see a short paper by PA Consultancy (who have been doing the option appraisal on possible PPP arrangements for BPL) addressing the impact on BPL of a decision by Government to switch to recombinant clotting factors for all haemophilia patients in England. The conclusions, I'm relieved to say, are in line with my advice to Lord Hunt and SofS last week.



Recombinant Clotting Factors. Impact o